NCODA/LinkedIn
Apr 20, 2025, 08:05
NCODA updated cabozantinib Treatment Support Kit
NCODA shared a post on LinkedIn:
“As treatment options expand, so do opportunities to offer meaningful support.
With cabozantinib’s new indication for neuroendocrine tumors (NETs), we’ve updated our complimentary Treatment Support Kit (TSK) to better reflect patients’ current needs—preserving core resources while introducing the most relevant new tools.
The refreshed kit includes urea-based skin cream to help manage skin-related side effects, replacing the pill container to better align with the treatment experience. The kit continues to include helpful essentials like loperamide, treatment calendars, diarrhea management education, and more.
Explore all kits and order.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 26, 2025, 08:40
Jul 26, 2025, 08:13
Jul 26, 2025, 07:32
Jul 26, 2025, 06:44
Jul 26, 2025, 06:11
Jul 26, 2025, 04:02
Jul 26, 2025, 03:52
Jul 26, 2025, 03:45
Jul 26, 2025, 03:33